Wave Life Sciences Ltd. is a biotech firm developing precision nucleic acid-based medicines for serious diseases via stereopure oligonucleotides.

# Wave Life Sciences Ltd. - Company Summary

## Overview
Wave Life Sciences Ltd. is a biotechnology company focused on the development of precision medicines using nucleic acid-based therapeutic platforms. The company specializes in designing stereopure oligonucleotides aimed at treating serious and life-threatening diseases through highly specific and effective genetic and molecular interventions.

## Business Focus & Strategies
- **Core Technology:** Proprietary platform utilizing stereopure oligonucleotides, enabling precise targeting of genetic sequences.
- **Pipeline Development:** Advancement of multiple therapeutic candidates across various diseases, including:
  - Obesity (WVE-007)
  - Alpha-1 antitrypsin deficiency (WVE-006)
  - Duchenne muscular dystrophy (WVE-N531)
  - Huntington’s disease (WVE-003)
  - Various GalNAc-AIMer programs targeting cardiometabolic diseases (e.g., PNPLA3, LDLR, APOB)
- **Strategic Collaborations:** Partnership with GSK for research, development, and commercial rights, including license agreements and milestone-based payments.
- **Pipeline Progress:** Achieved key milestones such as candidate selection, clinical trial applications, and positive interim clinical results demonstrating efficacy and safety.

## Operations
- **Employees:** Not specifically listed, but given the size and scope of the company, likely a specialized team involved in R&D, legal, regulatory, and corporate functions.
- **Customers:** Not explicitly listed; typical customers include biotech and pharma companies through collaborations, licensing, and development services.

## Financials
- **Revenue:** Not reported in the provided documents.
- **Net Income:** Not reported; as a development-stage biotech, likely not yet profitable.
- **Market Capitalization:** As of the most recent valuation, approximately **$488.7 million** based on market value of outstanding shares held by non-affiliates.

## Shareholder Data
- **Outstanding Shares (as of March 31, 2025):** 154,089,713 ordinary shares
- **Major Shareholders:**
  - RA Capital Management, L.P.: 15.76%
  - GSK plc: 10.89%
  - Adage Capital Partners, L.P.: 6.30%
  - Shin Nippon Biomedical Laboratories, Ltd.: 6.08%
  - BlackRock, Inc.: 6.07%

## Key Executive & Board
- **President & CEO:** Paul B. Bolno, M.D., MBA
- **Employees & Officers:** Includes senior leaders in R&D, finance, corporate development, and technical platforms.

---
*Note:* Specific data such as total revenue, net income, and exact employee count are not provided within the submitted documentation. The summary is based solely on the details available from the SEC filing excerpt.

Wave Life Sciences Ltd. is a biotechnology company dedicated to developing precision oligonucleotide therapies for severe genetic diseases using its proprietary PRISM™ technology platform.

# Company Overview: Wave Life Sciences Ltd.

## Business Description
Wave Life Sciences Ltd. is a biotechnology company focused on developing a new class of medicines using nucleic acid therapeutics, specifically oligonucleotide-based therapies. The company aims to address severe genetic diseases through its proprietary technology platform, PRISM™ (pharmacologically optimized RNA targeting). Wave is dedicated to developing its drug candidates with precision stereochemistry to enhance therapeutic efficacy and minimize potential side effects.

## Product Development
Wave Life Sciences is primarily engaged in the research, development, and commercialization of innovative therapeutics aimed at treating genetic diseases. Their product pipeline includes multiple clinical trials and preclinical studies focused on conditions such as:
- Alpha-1 Antitrypsin Deficiency (AATD)
- Duchenne Muscular Dystrophy (DMD)
- Huntington's Disease (HD)

Wave's development strategy emphasizes collaboration with major pharmaceutical companies, including partnerships with GlaxoSmithKline (GSK) and Takeda Pharmaceutical Company, which provide additional resources and expertise in advancing their therapeutic programs.

## Corporate Structure
- **Type**: Publicly traded company
- **Incorporated**: Singapore
- **Employees**: Over 100 employees (exact number not specified)
- **Headquarters**: 7 Straits View #12-00, Marina One East Tower, Singapore

## Financial Performance (as of Fiscal Year Ended December 31, 2023)
- **Revenue**: The company reported total revenue of approximately **$82.6 million** for the fiscal year ended December 31, 2023, driven primarily by collaboration agreements and grant revenues.
- **Net Loss**: The net loss for the year was approximately **$62.4 million**. This loss reflects the company's investments in research and development as well as general and administrative expenses necessary for growth and advancement of its therapeutic pipeline.

## Customer Base
Wave Life Sciences targets its products toward genetic disease patients, healthcare providers specializing in genetic diseases, and pharmaceutical partners engaged in collaborative therapeutic development. While specific customer numbers are not disclosed, the company is likely to have relationships with healthcare institutions, research organizations, and its collaboration partners.

## Market Position
Wave Life Sciences is positioned within the biotechnology industry, particularly in the nascent field of nucleic acid therapeutics. Their innovative approach to stereopure medicines gives them a unique market advantage. The emphasis on collaborations with renowned pharmaceutical partners amplifies their credibility and market footprint.

As they advance their product pipeline and collaborate with established firms, Wave Life Sciences aims to expand its impact on the treatment of genetic diseases and improve patient outcomes with its unique therapeutic solutions.

## Summary
In summary, Wave Life Sciences Ltd. is a pioneering biotechnology company with a focus on developing cutting-edge oligonucleotide therapies for genetic diseases, reporting significant revenue streams through collaborations and partnerships, and positioning itself for ongoing innovation in the therapeutic space.

Wave Life Sciences Ltd.

10-K / April 29, 2025

10-K / April 29, 2024

10-K / April 29, 2025

Wave Life Sciences Ltd. - Company Summary

Overview

Business Focus & Strategies

Operations

Financials

Shareholder Data

Key Executive & Board